The Next Chapter for Aastrom

Our recent decision to implement a strategic change in our R&D programs to focus on the development of ixmyelocel-T for the treatment of dilated cardiomyopathy (DCM) and stop enrollment in the Phase 3 REVIVE trial in critical limb ischemia (CLI) reflects the...

The Evolution of Cell Therapy

As clinical stage research involving stem cells has expanded during the past decade, so has public debate regarding the relative advantages and disadvantages of embryonic versus adult stem cells.  Ethical concerns about the use of embryonic stem cells have dominated...